Cambridge Investment Research Advisors, Inc. Altimmune, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.9 Billion
- Q4 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Altimmune, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 14,521 shares of ALT stock, worth $87,852. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,521
Previous 12,121
19.8%
Holding current value
$87,852
Previous $74,000
41.89%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ALT
# of Institutions
206Shares Held
39.3MCall Options Held
1.93MPut Options Held
1.4M-
Black Rock Inc. New York, NY5.32MShares$32.2 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN5.25MShares$31.8 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.43MShares$26.8 Million0.0% of portfolio
-
State Street Corp Boston, MA3.47MShares$21 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$16.6 Million1.49% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $297M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...